A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas

S. J. Kim, D. Y. Shin, J. S. Kim, D. H. Yoon, W. S. Lee, H. Lee, Y. R. Do, H. J. Kang, H. S. Eom, Y. H. Ko, S. H. Lee, H. Y. Yoo, M. Hong, C. Suh, W. S. Kim

Research output: Contribution to journalArticlepeer-review

26 Citations (Scopus)

Fingerprint

Dive into the research topics of 'A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas'. Together they form a unique fingerprint.

Medicine & Life Sciences